Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance. This is page number 17.

Order by Relevance | Date

Total 36353 results found since Jan 2013.

Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer & ndash; toxicities and response assessment
Source: Cancer Management and Research - March 18, 2018 Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research

Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy
Source: OncoTargets and Therapy - March 22, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer
We aimed to explore the efficacy and safety profile of preoperative neoadjuvant chemoradiation (NACRT) in locally advanced rectal cancer (LARC) in upper rectum versus middle/lower rectum.
Source: Radiation Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Ming-Yii Huang, Hsin-Hua Lee, Hsiang-Lin Tsai, Ching-Wen Huang, Yung-Sung Yeh, Cheng-Jen Ma, Chun-Ming Huang, Chiao-Yun Chen, Joh-Jong Huang and Jaw-Yuan Wang Tags: Research Source Type: research

Dosimetric benefit of adaptive radiotherapy in the neoadjuvant management of canine and feline thymoma —An exploratory case series
Veterinary and Comparative Oncology, EarlyView.
Source: Veterinary and Comparative Oncology - January 8, 2018 Category: Veterinary Research Source Type: research

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II & ndash;III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy
Source: OncoTargets and Therapy - April 5, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
The mechanistic target of rapamycin (mTOR) has been implicated in driving tumor biology in multiple malignancies, including urothelial carcinoma (UC). We investigate how mTOR and phosphorylated mTOR (pmTOR) protein expression correlate with chemoresponsiveness in the tumor and its microenvironment at final pathologic staging after neoadjuvant chemotherapy (NAC).
Source: Urologic Oncology: Seminars and Original Investigations - April 12, 2018 Category: Urology & Nephrology Authors: Brian R. Winters, Funda Vakar-Lopez, Lisha Brown, Bruce Montgomery, Roland Seiler, Peter C. Black, Joost L. Boormans, Marc Dall ′Era, Elai Davincioni, James Douglas, Ewan A. Gibb, Bas W.G. van Rhijn, Michiel S. van der Heijden, Andrew C. Hsieh, Jonathan Tags: Original article Source Type: research

Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
Source: OncoTargets and Therapy - April 11, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

OV21/PETROC: A Randomized Gynecologic Cancer Intergroup Phase II Study of Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery in Epithelial Ovarian Cancer
(Abstracted from Ann Oncol 2018;29(2):431–438) The use of neoadjuvant chemotherapy (NACT) prior to surgical debulking is increasingly used for advanced epithelial ovarian cancer (EOC). In women with EOC, the principal site of disease is the peritoneal cavity. As a means of increasing the dose intensity delivered to the tumor, intraperitoneal (IP) chemotherapy has been investigated. Three randomized clinical trials and a meta-analysis have demonstrated improved survival for women with stage III EOC who—following optimal, primary debulking surgery—received a combination of intravenous (IV) and IP chemotherapy. Updated...
Source: Obstetrical and Gynecological Survey - April 1, 2018 Category: OBGYN Tags: Gynecology: Gynecologic Oncology Source Type: research

Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands
Primary debulking surgery (PDS) followed by adjuvant chemotherapy is historically recommended as first line treatment for advanced stage ovarian cancer. Two randomized controlled trials, however, showed similar efficacy and reduced toxicity with neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Nevertheless, uptake of NACT-IDS varies widely between hospitals, which cannot be explained by difference in patient populations. In this survey, we therefore aimed to evaluate the views on NACT-IDS among all Dutch gynaecologists and medical oncologists involved in the treatment of ovarian cancer.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - February 28, 2018 Category: OBGYN Authors: M. Timmermans, G.S. Sonke, W.J. van Driel, R.I. Lalisang, P.B. Ottevanger, C.D. de Kroon, K.K. Van de Vijver, M.A. van der Aa, R.F. Kruitwagen Tags: Full length article Source Type: research

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy
The mechanistic target of rapamycin (mTOR) has been implicated in driving tumor biology in multiple malignancies, including urothelial carcinoma (UC). We investigate how mTOR and phosphorylated mTOR (pmTOR) protein expression correlate with chemoresponsiveness in the tumor and its microenvironment at final pathologic staging after neoadjuvant chemotherapy (NAC).
Source: Urologic Oncology: Seminars and Original Investigations - April 12, 2018 Category: Urology & Nephrology Authors: Brian R. Winters, Funda Vakar-Lopez, Lisha Brown, Bruce Montgomery, Roland Seiler, Peter C. Black, Joost L. Boormans, Marc Dall ′Era, Elai Davincioni, James Douglas, Ewan A. Gibb, Bas W.G. van Rhijn, Michiel S. van der Heijden, Andrew C. Hsieh, Jonathan Tags: Original article Source Type: research

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future
Approximately half of patients who undergo radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) will succumb to metastatic disease. We summarize the evidence for neoadjuvant radiation (NAR), chemo (NAC), and immunotherapy (checkpoint inhibition) prior to RC for MIBC.
Source: Urologic Oncology: Seminars and Original Investigations - November 8, 2017 Category: Urology & Nephrology Authors: Tom J.N. Hermans, Charlotte S. Voskuilen, Michiel S. van der Heijden,, Bernd J. Schmitz-Dr äger, Wassim Kassouf, Roland Seiler, Ashish M. Kamat, Petros Grivas, Anne E. Kiltie, Peter C. Black, Bas W.G. van Rhijn Tags: Seminars article Source Type: research

18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study
Pathologic response to neoadjuvant chemotherapy (neoCTX) is a prognostic factor in many cancer types, and early prediction would help to modify treatment. In patients with gastric and esophagogastric junction ...
Source: BMC Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Paul M. Schneider, Dilmurodjon Eshmuminov, Tamara Rordorf, Diana Vetter, Patrick Veit-Haibach, Achim Weber, Peter Bauerfeind, Panagiotis Samaras and Kuno Lehmann Tags: Research article Source Type: research

Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta ‐analysis
Journal of Thrombosis and Haemostasis, EarlyView.
Source: Journal of Thrombosis and Haemostasis - June 8, 2018 Category: Hematology Authors: M. Di Nisio , M. Candeloro , A. W. S. Rutjes , E. Porreca Source Type: research

Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
Source: OncoTargets and Therapy - July 22, 2018 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research

A successful case of neoadjuvant chemotherapy and radical hysterectomy during pregnancy for advanced uterine cervical cancer accompanied by neonatal erythroderma
Journal of Obstetrics and Gynaecology Research, EarlyView.
Source: Journal of Obstetrics and Gynaecology Research - July 25, 2018 Category: OBGYN Authors: Kayo Kayahashi , Yasunari Mizumoto , Subaru Myojo , Yusuke Mitani , Atsushi Tajima , Hiroshi Fujiwara Source Type: research